Mapping the risk of yellow fever infection

Current Infectious Disease Reports

Volumn 14, Issue 3, 2012, Pages 246-255

  Hill, David R ^a  

^a Quinnipiac University   (United States)

Author keywords

Adverse events; Africa; Epidemiology; Neurologic; Risk mapping; SouthAmerica; Viscerotropic; Yellow fever

Indexed keywords

BACTERIUM ANTIBODY; YELLOW FEVER VACCINE;

ALTITUDE; ARTICLE; DIGESTIVE SYSTEM DISEASE; DISEASE CARRIER; DISEASE SURVEILLANCE; DRUG SAFETY; ENDEMIC DISEASE; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; NEUROLOGIC DISEASE; NONHUMAN; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE; TREATMENT INDICATION; VACCINATION REACTION; VEGETATION; VIRUS TRANSMISSION; YELLOW FEVER;

EID: 84865634052     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0256-6     Document Type: Article

References (53)

1. Informal Working Group on Geographic Risk of Yellow Fever, World Health Organization. Background for the consultation on yellow fever and international travel, 2010 (update February 2011). 2011, World Health Organization: Geneva. p. 1-47. Available at: Http://www.who.int/ith/YFrisk.pdf. Provides all of the background information and rationale for YF risk categorisation. 2. 9.
2. Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: Consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11:622-32. Definitive paper describing the process and outcomes of the YF risk mapping.
3. World Health Organization. Revised recommendations for yellow fever vaccination for international travellers, 2011. Wkly Epidemiol Rec. 2011;86:401-11.
4. World Health Organization. International travel and health. Geneva: World Health Organization; 2011.
5. Centers for Disease Control and Prevention. CDC health information for international travel 2012. Atlanta: US Department of Health and Human Services, Public Health Service; 2011.
6. World Health Organization. Yellow fever surveillance and outbreak response: revision of case definitions, October 2010. Wkly Epidemiol Rec. 2010;85:465-72. Review and publication of new case definitions for YF surveillance.
7. World Health Organization. Yellow fever in the WHO African and American Regions, 2010. Wkly Epidemiol Rec. 2011;86:370-6.
8. World Health Organization. International Health Regulations (2005) Geneva: World Health Organization; 2005. p. 1-60.
9. Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59:895-900. (Pubitemid 12155776)
10. Coulange Bodilis H, Benabdelmoumen G, Gergely A, et al. Long term persistence of yellow fever neutralising antibodies in elderly persons. Bull Soc Pathol Exot. 2011;104:260-5.
11. Sawyer WA. The present geographic distribution of yellow fever and its significance. In: The Harvey lectures. New York: The Williams & Wilkins Company; 1936. p. 66-92.
12. Theiler M. Susceptibility of white mice to the virus of yellow fever. Science. 1930;71:367.
13. Sawyer WA, Lloyd W. The use of mice in tests of immunity against yellow fever. J Exp Med. 1931;54:533-55.
14. Van Rooyan C, Rhodes A. Virus diseases of man. 2nd ed. New York: Nelson; 1948.
15. United Nations Relief and Rehabilitation Administration. Third report of the expert commission on quarantine. Epidemiol Inf Bull. 1945;1:687-701.
16. Smith HH. Controlling yellow fever. In: Strode GK, editor. Yellow fever. New York: McGraw-Hill Book Co; 1951. p. 539-628.
17. Bonnel PH, Deutschman Z. La fièvre jaune en Afrique au cours des années récentes. Bull WHO. 1954;11:325-89.
18. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077-82.
19. World Health Organization. Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol Rec. 2008;83:105.
20. World Health Organization. Yellow fever in Africa and Central and South America, 2008-2009. Wkly Epidemiol Rec. 2011;86:25-36.
21. Holzmann I, Agostini I, Areta JI, et al. Impact of yellow fever outbreaks on two howler monkey species (Alouatta guariba clamitans and A. caraya) in Misiones, Argentina. Am J Primatol. 2010;72:475-80.
22. Vasconcelos PF. Yellow fever in Brazil: Thoughts and hypotheses on the emergence in previously free areas. Rev Saúde Pública. 2010;44:1144-9. Thoughtful consideration of risk factors for reemergence of YF in São Paolo State in Brazil.
23. Moreno ES, Rocco IM, Bergo ES, et al. Reemergence of yellow fever: Detection of transmission in the State of São Paulo, Brazil, 2008. Rev Soc Bras Med Trop. 2011;44:290-6.
24. Briand S, Beresniak A, Nguyen T, et al. Assessment of yellow fever epidemic risk: An original multi-criteria modeling approach. PLoS Negl Trop Dis. 2009;3:e483.
25. Taylor RM. Epidemiology. In: Strode GK, editor. Yellow fever. New York: McGraw-Hill Book Co; 1951. p. 427-538.
26. Camara FP, Gomes AL, Carvalho LM, Castello LG. Dynamic behavior of sylvatic yellow fever in Brazil (1954-2008). Rev Soc Bras Med Trop. 2011;44:297-9. Investigates the occurrence of YF epidemics in Brazil over several decades and determines that there is a 7 year cycle in central-western regions and a 14 year cycle in the northern region.
27. Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: A report of two cases. Lancet. 2001;358:91-7. (Pubitemid 32709846)
28. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: A report of four cases. Lancet. 2001;358:98-104. (Pubitemid 32709847)
29. Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001;358:121-2. (Pubitemid 32709852)
30. Adhiyaman V, Oke A, Cefai C. Effects of yellow fever vaccination. Lancet. 2001;358:1907-8.
31. Troillet N, Laurencet F. Effects of yellow fever vaccination. Lancet. 2001;358:1908-9.
32. Werfel U, Popp W. Effects of yellow fever vaccination. Lancet. 2001;358:1909.
33. Centers for Disease Control and Prevention. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR. 2001;50:643-5.
34. Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR RecommRep. 2010;59:1-27.
35. Thomas RE, Lorenzetti DL, SpraginsW, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-Associated serious adverse events: Systematic review. Vaccine. 2011;29:4544-55. Comprehensive review of the literature for SAE associated with YF vaccination.
36. Thomas RE, Lorenzetti DL, Spragins W, et al. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV + individuals, and older persons: Systematic review. Am J Trop Med Hyg. 2012;86:359-72. Sub-Analysis of SAE in persons with special health needs who have received YF vaccination.
37. Thomas RE, Lorenzetti DL, Spragins W, et al. Reporting rates of yellow fever vaccine 17D or 17DD-Associated serious adverse events in pharmacovigilance data bases: Systematic review. Curr Drug Saf. 2011;6:145-54.
38. Nishioka SD, Nunes-Araujo FRF, Pires WP, et al. Yellow fever vaccination during pregnancy and spontaneous abortion: A casecontrol study. Trop Med Int Health. 1998;3:29-33. (Pubitemid 28081016)
39. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002;85:131-4.
40. Mota LM, Oliveira AC, Lima RA, et al. Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop. 2009;42:23-7.
41. Seligman SJ. Yellow fever virus vaccine-Associated deaths in young women. Emerg Infect Dis. 2011;17:1891-3. Analysis of nine cases of fatal YELAVD, all of which occurred in women aged 19-34 years.
42. Barwick Eidex R, for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination (letter). Lancet. 2004;364:936.
43. Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans Roy Soc Trop Med Hyg. 2007;101:967-71. (Pubitemid 47317251)
44. Bae HG, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis. 2008;197:1577-84. (Pubitemid 351706488)
45. Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine-Associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis. 2008;198:500-7.
46. Barrett AD, Teuwen DE. Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21:308-13. Review of the possible pathogenic mechanisms for SAE in YF vaccine recipients.
47. Silva ML, Espirito-Santo LR,Martins MA, et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol. 2010;17:118-26.
48. Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: A prospective controlled cohort study. PLoS ONE. 2011;6:e27753. Demonstration of how persons aged ≥60 years handle YF vaccine virus, compared with a younger cohort.
49. Centers for Disease Control and Prevention. Transmission of yellow fever vaccine virus through breast-feeding-Brazil, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:130-2.
50. Traiber C, Coelho-Amaral P, Ritter VR, Winge A. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted by breast milk. J Pediatr (Rio J). 2011;87:269-72.
51. Kuhn S, Twele-Montecinos L, MacDonald J, et al. Case report: Probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ. 2011;183:E243-5. One of three cases of YF vaccine virus transmission to infants who are breast-feeding.
52. Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011;364:1326-33. Trial of an inactivated YF vaccine demonstrating good immunogenicty and tolerabilty.
53. McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases. Vaccine. 2007;25:1727-34. (Pubitemid 46188373)